![]() ![]() Where R 1 is a leaving group, to N-(2-hydroxyisobutyl)-phthalimide (2) (b) converting MIBOL to 2-methoxyisobutylamine (MIBA), andĪnother aspect of the invention is a method of preparing MIBI by (a) converting 2,2-dimethyloxirane to 2-methoxyisobutanol (MIBOL), One aspect of the invention is a method of preparing MIBI by The present invention is directed to new methods of preparing 2-methoxyisobutylisonitrile (MIBI) and metal isonitrile complexes, such as tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate (BF 4), and novel compounds useful in their preparation. ![]() However, there is a continuing need for improved methods of preparing MIBI and metal complexes thereof, such as BF 4. Prior methods of preparing MIBI are described in U.S. It is not readily achieved because there is no commercially available chemical having a related structure. The synthesis of MIBI has been extensively studied over the past twenty five years. Pharmacopoeia (29 th Ed.) requires that a mean of not less than 90% (corrected area percentage) of the total radioactivity is represented by 99mTc-Sestamibi, and a mean of not more than 5% (corrected area percentage) of the total radioactivity is present as 99mTc pentamibi dimethylvinyl isonitrile. Prior to use, the lyophilized mixture is reconstituted with sodium pertechnetate ( 99mTc) and boiled to form technetium ( 99mTc) Sestamibi. ![]() The kit includes a lyophilized mixture of a copper complex of MIBI (tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate (BF 4)) as the active ingredient, sodium citrate dihydrate as a buffer, L-cysteine hydrochloride monohydrate as a stabilization aid, mannitol as a lyophilization aid, and stannous chloride dihydrate as a reducing agent. Discovered in 1981 by Alan Davison, it received FDA approval in 1990 and it has been sold commercially since February 1991. This radiopharmaceutical, which is commercially available in the form of a kit under the tradenames CARDIOLITE® and MIRALUMA®, is useful for detecting coronary artery disease as well as evaluating breast lesions by planar imaging. Methoxyisobutylisonitrile (MIBI) is a key starting material in the preparation of the complex technetium ( 99mTc) hexakis(2-methoxyisobutylisonitrile) (technetium ( 99mTc) Sestamibi). ![]() The present invention relates to new syntheses of 2-methoxyisobutylisonitrile and metal isonitrile complexes, such as tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate, which are used in the preparation of technetium ( 99mTc) Sestamibi. 30, 2006, both of which are hereby incorporated by reference. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
January 2023
Categories |